The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors.
 
Desamparados Roda
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - SERVIER
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Celgene; Roche/Genentech; Sanofi
 
Elena Garralda
Employment - Next Oncology
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Anaveon; Boehringer Ingelheim; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Incyte; Janssen; MAB Discovery; Medscape; Roche; Sanofi; Seagen; Thermo Fisher Scientific
Speakers' Bureau - MSD; Novartis; Roche; Seagen; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; Exelixis; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Hani M. Babiker
Consulting or Advisory Role - Celgene; Endocyte; Idera; Myovant Sciences; Novocure
Speakers' Bureau - Guardant Health
 
Peter John Oppelt
Research Funding - Enzychem Lifesciences (Inst); HiFiBiO Therapeutics (Inst); Merck (Inst)
 
Xi Lin
Employment - HiFiBiO Therapeutics
 
Shaozhen Xie
Employment - HiFiBiO Therapeutics
Consulting or Advisory Role - Geode Therapeutics (I)
 
Margaret E Chen
Employment - HiFiBiO Therapeutics
 
Jinping Gan
Employment - HiFiBiO Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene; Merck; Pfizer
 
Gabrielle Wong
Employment - HiFiBiO Therapeutics; Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - HiFiBiO Therapeutics; Novartis Institutes for BioMedical Research
Patents, Royalties, Other Intellectual Property - Patent for KAZ954
 
Jack Russella Pollard
Employment - HiFiBiO Therapeutics; Moderna Therapeutics; Sanofi
Stock and Other Ownership Interests - Moderna Therapeutics; sanofi
 
William Hedrich
No Relationships to Disclose
 
John Pallante
Employment - HiFiBiO Therapeutics
 
Christos Hatzis
Employment - HiFiBiO Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Robert H Andtbacka
Employment - HiFiBiO Therapeutics; Merck Sharp & Dohme (I); Seven and Eight Biopharmaceuticals
Stock and Other Ownership Interests - Merck Sharp & Dohme (I)